CMIC HOLDINGS Co.,Ltd. (E05292) Stock Price

Symic Holdings and its group companies operate a unique business model called "PVC (Pharmaceutical Value Creator)" that supports the entire value chain of pharmaceutical companies. This model comprises three core businesses: CRO (Contract Research Organization) services for drug development support, CDMO (Contract Development and Manufacturing Organization) services for pharmaceutical formulation development and manufacturing support, and Market Solutions services including pharmaceutical sales support, development, manufacturing, sales, and distribution of orphan drugs and related solutions. The CRO business provides comprehensive support for disease prevention and treatment research and development, from consulting through regulatory filing. The CDMO business handles development and manufacturing of pharmaceutical formulations and biological active ingredients, from clinical trial drugs to commercial products. The Market Solutions business offers medical affairs, sales, and marketing support to pharmaceutical companies, while also providing solutions that address unmet medical needs.

Additionally, the company operates a "Healthcare Solutions" business segment, which includes Site Support Solutions and Healthcare Revolution. The Site Support Solutions business provides comprehensive support to medical facilities and healthcare professionals under the concept of "from the lifetime of medicine to the lifetime of people," contributing to improved healthcare access. The Healthcare Revolution business aims to build a new healthcare ecosystem utilizing digital technology, including harmo, a Healthcare Communication Channel with electronic medication notebook functionality. Through these businesses, Symic Holdings provides a wide range of healthcare solutions not only to the pharmaceutical industry but also to individuals and local governments.

Symic Holdings aims to contribute to society by providing innovative solutions in the medical and healthcare sectors. The company has developed a medium-term management plan and is focusing on priority areas to adapt to changes in the pharmaceutical industry and achieve sustainable growth.

The company's growth strategy involves transitioning from "PVC (Pharmaceutical Value Creator)," which comprehensively supports pharmaceutical companies' value chains, to "PHVC (Personal Health Value Creator)." This shift aims to transform the business model to maximize individual health value.

Key initiatives include advancing healthcare business, strengthening comprehensive support from disease prevention and treatment research and development through sales, and contributing to a sustainable society through socially beneficial businesses. Through these efforts, the company is creating new healthcare businesses that address diverse individual health needs and advancing total disease care spanning prevention, diagnosis, treatment, and prognosis.

Additionally, the company is promoting digitalization and strengthening pharmaceutical development through new drug discovery platform technologies to accelerate and improve the efficiency of drug development. These efforts support the development of "healthcare professionals" who contribute to maintaining medical and care systems, while promoting business activities that protect the environment and ensure employee health and safety.

Through these strategies, Symic Holdings provides comprehensive healthcare solutions not only to the pharmaceutical industry but also to individuals and municipalities, contributing to medical advancement and public health.